dc.contributor.author
Messerschmidt, Clemens
dc.contributor.author
Obermayer, Benedikt
dc.contributor.author
Klinghammer, Konrad
dc.contributor.author
Ochsenreither, Sebastian
dc.contributor.author
Treue, Denise
dc.contributor.author
Stenzinger, Albrecht
dc.contributor.author
Glimm, Hanno
dc.contributor.author
Fröhling, Stefan
dc.contributor.author
Kindler, Thomas
dc.contributor.author
Brandts, Christian H.
dc.contributor.author
Schulze‐Osthoff, Klaus
dc.contributor.author
Weichert, Wilko
dc.contributor.author
Tinhofer, Ingeborg
dc.contributor.author
Klauschen, Frederick
dc.contributor.author
Keilholz, Ulrich
dc.contributor.author
Beule, Dieter
dc.contributor.author
Rieke, Damian T.
dc.date.accessioned
2022-02-18T09:30:01Z
dc.date.available
2022-02-18T09:30:01Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/34054
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-33772
dc.description.abstract
Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (n = 496) and a validation set (DKTK MASTER cohort, n = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately reanalyzed. APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. This association was restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-negative subgroup was identified, that showed higher T-cell inflammation and immune checkpoint expression, as well as expression of APOBEC3 genes. Mutations in immune-evasion pathways were also enriched in these tumors. Analysis of single-cell sequencing data identified expression of APOBEC3B and 3C genes in malignant cells. We identified an APOBEC-enriched subgroup of HPV-negative HNSCC with a distinct immunogenic phenotype, potentially mediating response to immunotherapy.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
immune checkpoint inhibition
en
dc.subject
head and neck cancer
en
dc.subject
mutational signature
en
dc.subject
tumor inflammation
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Distinct immune evasion in APOBEC‐enriched, HPV‐negative HNSCC
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1002/ijc.33123
dcterms.bibliographicCitation.journaltitle
International Journal of Cancer
dcterms.bibliographicCitation.number
8
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
2293
dcterms.bibliographicCitation.pageend
2302
dcterms.bibliographicCitation.volume
147
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
32468570
dcterms.isPartOf.issn
0020-7136
dcterms.isPartOf.eissn
1097-0215